Kirsten Castillo
Kirsten Castillo's purchase track record
Kirsten Castillo has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/14/2025 | ACVA | $125K | +5.9% | -5.1% | +10.0% |
| 11/22/2024 | OCGN | $23K | -25.0% | +2.6% | -2.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Ocugen Secures Bahamas Approval for Gene Therapy OCU400. Ocugen received provisional approval from the Bahamas regulator to supply its gene‑therapy OCU400 for retinitis pigmentosa. The company will provide the treatment through an expanded access program and aims to treat the first patient within 90 days. The approval also grants priority designation under the Bahamas Longevity and Regenerative Therapies Act. This development may broaden global access for Ocugen’s therapy.
Transaction History
| ACVA | ▲ Buy | Grant | 27,500 | $0 | 5/27/2026 | View on chart |
| ACVA | ▲ Buy | Open Market | 5,000 | $31K | 11/17/2025 | View on chart |
| ACVA | ▲ Buy | Open Market | 15,000 | $94K | 11/14/2025 | View on chart |
| ACVA | ▲ Buy | Grant | 9,868 | $0 | 5/28/2025 | View on chart |
| OCGN | ▲ Buy | Open Market | 25,000 | $23K | 11/22/2024 | View on chart |
| ACVA | ▼ Sell | Open Market | 5,000 | $89K | 6/7/2024 | View on chart |
| ACVA | ▲ Buy | Option Exercise | 5,000 | — | 6/7/2024 | View on chart |
| ACVA | ▲ Buy | Option Exercise | 15,000 | — | 6/6/2024 | View on chart |
| ACVA | ▼ Sell | Open Market | 15,000 | $265K | 6/6/2024 | View on chart |
| ACVA | ▲ Buy | Grant | 9,239 | $0 | 5/29/2024 | View on chart |
| ACVA | ▲ Buy | Option Exercise | 30,000 | — | 8/11/2023 | View on chart |
| ACVA | ▼ Sell | Open Market | 30,000 | $471K | 8/11/2023 | View on chart |
| ACVA | ▲ Buy | Option Exercise | 36,583 | — | 5/24/2023 | View on chart |
| ACVA | ▼ Sell | Open Market | 36,583 | $634K | 5/24/2023 | View on chart |
| OCGN | ▲ Buy | Option Exercise | 42,000 | $12K | 8/11/2022 | View on chart |
| OCGN | ▼ Sell | Open Market | 42,000 | $122K | 8/11/2022 | View on chart |
| OCGN | ▼ Sell | Open Market | 15,000 | $225K | 11/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Copart extends tender offer to acquire ACV Auctions
Copart has announced an extension of its tender offer to acquire ACV Auctions. This development highlights ongoing interest in the company, with some analysts suggesting that current market conditions may be masking long-term growth potential. The stock is currently trading near its 52-week high, reflecting the attention surrounding the acquisition proposal.
Copart extends tender offer to acquire ACV Auctions. Copart has announced an extension of its tender offer to acquire ACV Auctions. This development highlights ongoing interest in the company, with some analysts suggesting that current market conditions may be masking long-term growth potential. The stock is currently trading near its 52-week high, reflecting the attention surrounding the acquisition proposal.